Open AccessOne year in review 2021: Behçet's syndrome
Author(s) -
Gülen Hatemi,
Emire Seyahi,
İzzet Fresko,
Rosaria Talarico,
Didar Uçar,
Vedat Hamuryudan
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/lnvc9k
Subject(s) - medicine , disease , tofacitinib , behcet's disease , apremilast , dermatology , thalidomide , intensive care medicine , psychological intervention , treatment modality , systemic disease , immunology , psoriatic arthritis , rheumatoid arthritis , psychiatry , multiple myeloma
This review aims to provide a critical digest of the recent studies that enhance our understanding of Behçet's syndrome by evaluating time trends, differences in disease course between men and women, and between patients with an early and late disease onset, progress in disease assessment, novel findings on immunopathogenesis and genetics, clinical features and differential diagnosis of eye, vascular, nervous system and gastrointestinal system involvement, and new data on treatment modalities including TNF-alpha, IL-17 and IL-6 inhibitors, tofacitinib, and apremilast, as well as surgical interventions.